Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40

Abstract Introduction Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma amyloid beta (Aβ)42/Aβ40 could predict continuous values...

Full description

Bibliographic Details
Main Authors:	Julie K. Wisch, Brian A. Gordon, Anna H. Boerwinkle, Patrick H. Luckett, James G. Bollinger, Vitaliy Ovod, Yan Li, Rachel L. Henson, Tim West, Mathew R. Meyer, Kristopher M. Kirmess, Tammie L.S. Benzinger, Anne M. Fagan, John C. Morris, Randall J. Bateman, Beau M. Ances, Suzanne E. Schindler
Format:	Article
Language:	English
Published:	Wiley 2023-01-01
Series:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:	biomarker concordance CSF Aβ42/Aβ40 machine learning PET plasma Aβ42/Aβ40
Online Access:	https://doi.org/10.1002/dad2.12405

Similar Items

Cerebrospinal fluid Aβ40 improves the interpretation of Aβ42 concentration for diagnosing Alzheimer’s disease.
by: Aline eDorey, et al.
Published: (2015-11-01)

Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels
by: Javier Pacheco-Quinto, et al.
Published: (2006-06-01)

Alzheimer’s Disease CSF Biomarkers as Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus
by: Efstratios-Stylianos Pyrgelis, et al.
Published: (2023-11-01)

Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
by: María Pascual-Lucas, et al.
Published: (2023-01-01)

A mix-and-click method to measure amyloid-β concentration with sub-micromolar sensitivity
by: Christine Xue, et al.
Published: (2017-01-01)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
by: Oskar Hansson, et al.
Published: (2019-04-01)

Correlation of Plasmatic Amyloid Beta Peptides (Aβ-40, Aβ-42) with Myocardial Injury and Inflammatory Biomarkers in Acute Coronary Syndrome
by: Luis Eduardo Del Moral, et al.
Published: (2024-02-01)

Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
by: Anders Sandberg, et al.
Published: (2022-12-01)

Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
by: Nai-Ching Chen, et al.
Published: (2020-04-01)

Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort
by: Hyemin Jang, et al.
Published: (2021-10-01)

Proanthocyanidins inhibit the secretion of Aβ1-42 induced by Aβ25-35 in human neuroblastoma cell line SH-SY5Y
by: LI Qi, ZHANG Xiao-qiang, TAO Yi-fan, ZHU Meng-wen, CUI Dan-dan, SUN Teng-teng
Published: (2021-05-01)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
by: Hans-Wolfgang Klafki, et al.
Published: (2022-12-01)

Definition of a Threshold for the Plasma Aβ42/Aβ40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia
by: Lise Colmant, et al.
Published: (2024-01-01)

An EWAS of dementia biomarkers and their associations with age, African ancestry, and PTSD
by: Mark W. Miller, et al.
Published: (2024-03-01)

The Influence of Lipid Electric Charge on the Binding of Aβ(1–42) Amyloid Peptide to Bilayers in the Liquid-Ordered State
by: Hasna Ahyayauch, et al.
Published: (2024-03-01)

Anti-Parallel β-Hairpin Structure in Soluble Aβ Oligomers of Aβ40-Dutch and Aβ40-Iowa
by: Ziao Fu, et al.
Published: (2021-01-01)

Coumarin derivatives against amyloid-beta 40 – 42 peptide and tau protein
by: Kowalczyk Joanna, et al.
Published: (2022-08-01)

Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status
by: Shogyoku Bun, et al.
Published: (2023-09-01)

Oligomeric and Fibrillar Species of Aβ42 Diversely Affect Human Neural Stem Cells
by: Adela Bernabeu-Zornoza, et al.
Published: (2021-09-01)

Effect of Continuous and Interval Training on Amyloid β 42 (Aβ42) and Malondialdehyde (MDA) Levels in Hippocampus of Elderly Rats
by: Zahra Barati, et al.
Published: (2021-12-01)

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment
by: Inês Baldeiras, et al.
Published: (2018-03-01)

The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
by: Michaela Amft, et al.
Published: (2022-04-01)

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
by: Laila Abdullah, et al.
Published: (2020-03-01)

Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology
by: Daniel J. Figdore, et al.
Published: (2024-01-01)

Cryptotanshinone against vascular dementia through inhibition of Aβ aggregation and inflammatory responses in cerebrovascular endothelial cells
by: Hongmei Ding, et al.
Published: (2022-12-01)

Anesthesia and surgery-induced elevation of CSF sTREM2 is associated with early cognitive dysfunction after thoracoabdominal aortic dissection surgery
by: Kexin Wang, et al.
Published: (2022-12-01)

Inhibition of autophagosome-lysosome fusion contributes to TDCIPP-induced Aβ1-42 production in N2a-APPswe cells
by: Chunli Zou, et al.
Published: (2024-04-01)

Anti-inflammatory and cognitive effects of interferon-β1a (IFNβ1a) in a rat model of Alzheimer’s disease
by: Giuseppa Mudò, et al.
Published: (2019-02-01)

Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease
by: Giau VV, et al.
Published: (2018-02-01)

Presenilin: A Multi-Functional Molecule in the Pathogenesis of Alzheimer’s Disease and Other Neurodegenerative Diseases
by: Yang Sun, et al.
Published: (2024-02-01)

Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
by: Liding Zhang, et al.
Published: (2021-11-01)

Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs
by: Sei-Kyoung Park, et al.
Published: (2016-01-01)

Plasma Biomarkers Ascertained With Immunomagnetic Reduction Diagnosing Early-Stage Alzheimer's Disease: A Systematic Review
by: Pui-Un Tang, et al.
Published: (2021-01-01)

Impacts of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in alzheimer’s disease
by: Xi-chen Zhu, et al.
Published: (2020-09-01)

Systematic characterization of a non-transgenic Aβ 1–42 amyloidosis model: synaptic plasticity and memory deficits in female and male mice
by: Raquel Jiménez-Herrera, et al.
Published: (2023-09-01)

Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury
by: Iftakher Hossain, et al.
Published: (2020-05-01)

Evidence for a Strong Relationship between the Cytotoxicity and Intracellular Location of β-Amyloid
by: Md. Aminul Haque, et al.
Published: (2022-04-01)

Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
by: Débora Lanznaster, et al.
Published: (2020-04-01)

Addition of Aβ42 to Total Cerebral Small Vessel Disease Score Improves the Prediction for Cognitive Impairment in Cerebral Small Vessel Disease Patients
by: Liu J, et al.
Published: (2021-01-01)

Explicating anti-amyloidogenic role of curcumin and piperine via amyloid beta (Aβ) explicit pathway: recovery and reversal paradigm effects
by: Aimi Syamima Abdul Manap, et al.
Published: (2020-09-01)